Physiomics bounces on first commercial contract

6th Jun 2013 10:02

Computer-aided biology provider Physiomics has signed a first contract to supply its Virtual Tumour service to a biotech company. The Aim company said it will receive an up-front fee to provide access to its technology as well as ongoing service fees as the project progresses.This is the Oxford-based systems biology company's first commercial contract for its Virtual Tumour Clinical platform.Physiomics said the project will begin immediately, with its technology used in conjunction with traditional techniques to guide client's clinicians in appropriate dosing and scheduling of their drug. Chief Executive Officer Dr. Mark Chadwick said: "Each new project that we complete will allow us to improve and extend the model and make it applicable to more oncology projects in future."Shares in Physiomics were up 47.6% at 0.14p at 10:10 on Thursday.OH